- Home
- BPTH vs MULN Comparison
BPTH vs MULN Comparison
Compare BPTH & MULN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPTH
- MULN
- Stock Information
- Founded
- BPTH 2007
- MULN 2014
- Country
- BPTH United States
- MULN United States
- Employees
- BPTH N/A
- MULN N/A
- Industry
- BPTH Biotechnology: Pharmaceutical Preparations
- MULN Auto Manufacturing
- Sector
- BPTH Health Care
- MULN Consumer Discretionary
- Exchange
- BPTH Nasdaq
- MULN Nasdaq
- Market Cap
- BPTH 4.0M
- MULN 4.1M
- IPO Year
- BPTH N/A
- MULN N/A
- Fundamental
- Price
- BPTH $0.82
- MULN $2.93
- Analyst Decision
- BPTH Strong Buy
- MULN
- Analyst Count
- BPTH 2
- MULN 0
- Target Price
- BPTH $30.00
- MULN N/A
- AVG Volume (30 Days)
- BPTH 107.7K
- MULN 5.5M
- Earning Date
- BPTH 11-15-2024
- MULN 08-12-2024
- Dividend Yield
- BPTH N/A
- MULN N/A
- EPS Growth
- BPTH N/A
- MULN N/A
- EPS
- BPTH N/A
- MULN N/A
- Revenue
- BPTH N/A
- MULN $156,570.00
- Revenue This Year
- BPTH N/A
- MULN N/A
- Revenue Next Year
- BPTH N/A
- MULN N/A
- P/E Ratio
- BPTH N/A
- MULN N/A
- Revenue Growth
- BPTH N/A
- MULN N/A
- 52 Week Low
- BPTH $0.61
- MULN $1.60
- 52 Week High
- BPTH $12.40
- MULN $2,100.00
- Technical
- Relative Strength Index (RSI)
- BPTH 40.36
- MULN 43.00
- Support Level
- BPTH $0.74
- MULN $2.53
- Resistance Level
- BPTH $0.85
- MULN $3.43
- Average True Range (ATR)
- BPTH 0.09
- MULN 0.53
- MACD
- BPTH -0.01
- MULN 0.50
- Stochastic Oscillator
- BPTH 53.85
- MULN 63.94
About BPTH Bio-Path Holdings Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
About MULN Mullen Automotive Inc.
Mullen Automotive Inc is engaged in manufacturing electric vehicles and energy solutions. The company strives to make electric vehicles more accessible by building an end-to-end ecosystem that takes care of all aspects of electric vehicle ownership. The Company owns and partners with several synergistic businesses, all working towards the same goal of creating clean and scalable electric vehicles and energy solutions. The company has two segments Bollinger and Mullen/ELMS, which generates revenue.